FREE Daily Stock Alerts From Stock-PR.com
BGMD, BG Medicine, Inc.
** BGMD reported that it has obtained a CE Mark enabling the commercial sale of the CardioSCORE(TM) test in the EU and other countries that recognize the CE Mark.
The CardioSCORE test is BGMD‘s patented diagnostic blood test designed to dramatically improve risk prediction of major cardiovascular events beyond traditional risk factor assessments, such as the Framingham Risk Score and European SCORE.
BGMD is a diagnostics company focused on the development and commercialization of novel cardiovascular tests to address significant unmet medical needs, improve patient outcomes and reduce healthcare costs.
More about BGMD at www.bg-medicine.com
Read Full Disclaimer at http://stock-pr.com/disclaimer